Anavex Announces Fiscal 2015 Year-End Financial Results

NEW YORK, NY – December 29, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported year-end results for fiscal year 2015. Financial…

ICV Manhattan 2015

Event: Corporate Overview by Christopher U. Missling, PhD, President and Chief Executive Officer Date/Time: Wednesday, December 9, 2015 9:10 a.m. ET Location: Mandarin Oriental, 36th Floor, 80 Columbus Circle Drive, New York, NY

Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.

NEW YORK, NY – December 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, has been…

Anavex Expands Management Team

NEW YORK, NY – December 2, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Ulrich Elben, PhD as Vice President of Preclinical Operations.…